Feedback / Questions
Cimerli (ranibizumab biosimilar) - Amneal, Formycon, Coherus Biosci, Teva
FYB202 (ustekinumab biosimilar) - Formycon
https://www.formycon.com/en/press-release/formycon-is-acquiring-the-biosimilar-assets-fyb201-and-fyb202-and-strengthening-its-position-in-the-global-growth-market-of-biosimilars-through-long-term-partnership-with-athos-kg/
Mar 29, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next